Pro-inflammatory cytokines such as TNF-a, IFN-γ, IL-6, Ccl5 and IL-12 were downregulated while CNS inflammation was also reduced showcasing a potential efficacy in MS (38). The gene discussed is IL6; the disease is myeloid sarcoma.